为肝细胞癌武装 GPC3 CAR T 细胞：多少才足够，下一步是什么？
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
98.9分
★★★★★
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
HBV 抗原作为 HBV 相关 HCC 过继性 TCR-T 细胞治疗中的肿瘤抗原：原理与临床有效性
英文原题：HBV antigen as a tumour antigen in adoptive TCR-T cell therapy for HBV-related HCC: rationale and clinical effectiveness.
研究概要
慢性HBV感染患者发生的肝细胞癌以通过高度组织特异性过程表达全部或部分HBV抗原为特征，这一过程由HBV的嗜肝性决定。
中文摘要
在HBV慢性感染患者中发生的肝细胞癌，其特征是通过高度组织特异性的过程表达全部或部分HBV抗原，这一过程由HBV的嗜肝性决定。因此，HBV抗原是过继性T细胞免疫治疗的一个可能靶点，因为它们的表达以及由此产生的潜在靶向非肿瘤事件仅限于肝脏区域，不涉及其他器官。在此，我们总结了在HBV相关HCC中利用病毒抗原作为肿瘤抗原开发T细胞疗法的研究步骤，并讨论了HBV特异性T细胞受体（TCR）重定向T细胞在I期临床试验中的疗效和潜在作用机制。
展开英文摘要原文
Hepatocellular carcinoma developing in patients with HBV chronic infection are marked by expression of whole or partial HBV antigens through a highly tissue-specific process, determined by the hepatotropism of HBV. HBV antigens are therefore a possible target for adoptive T cell immunotherapy as their expression and, consequently, potential on-target off-tumour events, are confined to the liver compartment with no involvement of other organs. Here we summarise the research steps to develop T cell therapy that utilises viral antigen as a tumour antigen in HBV-related HCC and discuss the efficacy and the potential mechanisms of action of HBV-specific T cell receptor (TCR)-redirected T cells in phase I clinical trials.
论文信息
- 作者
- He S、Tan AT、Bertoletti A
- 第一作者单位
- Programme Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.Singapore
- 通讯作者单位
- Programme Emerging Infectious Diseases, Duke-NUS Medical School, Singapore. Electronic address: antonio@duke-nus.edu.sg.Singapore
- 文献类型
- 综述
- 期刊
- Seminars in immunology2025 Dec
- 原文标识
- PubMed 41202736 · DOI 10.1016/j.smim.2025.102004